Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 15 | 2024 | 1275 | 2.930 |
Why?
|
| HIV Infections | 21 | 2024 | 4946 | 2.230 |
Why?
|
| Obesity | 6 | 2024 | 356 | 1.790 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 7 | 2024 | 76 | 1.710 |
Why?
|
| Pyridones | 8 | 2024 | 87 | 1.640 |
Why?
|
| Oxazines | 7 | 2024 | 71 | 1.610 |
Why?
|
| Piperazines | 7 | 2024 | 73 | 1.610 |
Why?
|
| Epidemics | 2 | 2024 | 64 | 1.590 |
Why?
|
| Anti-Obesity Agents | 1 | 2024 | 1 | 0.940 |
Why?
|
| HIV-1 | 6 | 2024 | 1239 | 0.860 |
Why?
|
| Tenofovir | 9 | 2024 | 158 | 0.850 |
Why?
|
| Humans | 25 | 2024 | 14077 | 0.820 |
Why?
|
| Research Personnel | 2 | 2021 | 19 | 0.810 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 112 | 0.740 |
Why?
|
| Folic Acid | 1 | 2021 | 12 | 0.740 |
Why?
|
| Drug Interactions | 1 | 2021 | 30 | 0.730 |
Why?
|
| Weight Gain | 4 | 2024 | 73 | 0.660 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2021 | 171 | 0.640 |
Why?
|
| Personnel Selection | 1 | 2018 | 1 | 0.640 |
Why?
|
| Interdisciplinary Research | 1 | 2018 | 2 | 0.630 |
Why?
|
| Social Networking | 1 | 2018 | 8 | 0.630 |
Why?
|
| Mentors | 1 | 2018 | 16 | 0.620 |
Why?
|
| Ambulatory Care | 1 | 2018 | 54 | 0.600 |
Why?
|
| Lost to Follow-Up | 1 | 2018 | 62 | 0.600 |
Why?
|
| Patient Compliance | 1 | 2018 | 120 | 0.580 |
Why?
|
| Emtricitabine | 5 | 2024 | 74 | 0.530 |
Why?
|
| Anti-Retroviral Agents | 5 | 2024 | 542 | 0.500 |
Why?
|
| Female | 11 | 2024 | 8751 | 0.430 |
Why?
|
| South Africa | 9 | 2024 | 7312 | 0.430 |
Why?
|
| Outpatients | 2 | 2023 | 36 | 0.430 |
Why?
|
| Treatment Outcome | 4 | 2023 | 867 | 0.430 |
Why?
|
| Adult | 10 | 2024 | 5664 | 0.370 |
Why?
|
| Adenine | 5 | 2023 | 88 | 0.350 |
Why?
|
| Pregnancy | 4 | 2021 | 1815 | 0.310 |
Why?
|
| Alanine | 3 | 2023 | 29 | 0.290 |
Why?
|
| Benzoxazines | 3 | 2023 | 119 | 0.280 |
Why?
|
| Research Design | 2 | 2023 | 123 | 0.250 |
Why?
|
| Alkynes | 2 | 2021 | 113 | 0.240 |
Why?
|
| Cyclopropanes | 2 | 2021 | 119 | 0.240 |
Why?
|
| Weight Loss | 1 | 2024 | 12 | 0.230 |
Why?
|
| Creatinine | 1 | 2024 | 51 | 0.230 |
Why?
|
| Thiazoles | 1 | 2022 | 6 | 0.210 |
Why?
|
| Male | 7 | 2024 | 6489 | 0.200 |
Why?
|
| Education, Graduate | 1 | 2021 | 10 | 0.190 |
Why?
|
| Social Stigma | 1 | 2021 | 76 | 0.190 |
Why?
|
| Africa | 2 | 2021 | 360 | 0.190 |
Why?
|
| Stillbirth | 1 | 2021 | 81 | 0.180 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 263 | 0.180 |
Why?
|
| Phosphorous Acids | 1 | 2019 | 14 | 0.170 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2021 | 507 | 0.160 |
Why?
|
| Pandemics | 1 | 2021 | 280 | 0.160 |
Why?
|
| Societies, Scientific | 1 | 2018 | 1 | 0.160 |
Why?
|
| Clinical Medicine | 1 | 2018 | 1 | 0.160 |
Why?
|
| HIV Integrase Inhibitors | 3 | 2024 | 29 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2018 | 48 | 0.150 |
Why?
|
| Survival Analysis | 1 | 2018 | 149 | 0.150 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 163 | 0.150 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 468 | 0.150 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2021 | 467 | 0.150 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 367 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2018 | 228 | 0.130 |
Why?
|
| Retrospective Studies | 1 | 2018 | 767 | 0.120 |
Why?
|
| Middle Aged | 4 | 2024 | 3425 | 0.120 |
Why?
|
| Child, Preschool | 1 | 2018 | 1675 | 0.110 |
Why?
|
| Lamivudine | 2 | 2024 | 86 | 0.110 |
Why?
|
| Pharmacogenetics | 2 | 2023 | 27 | 0.100 |
Why?
|
| Infant | 1 | 2018 | 2145 | 0.100 |
Why?
|
| Young Adult | 3 | 2024 | 2357 | 0.090 |
Why?
|
| Prodrugs | 2 | 2021 | 10 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 271 | 0.080 |
Why?
|
| Viral Load | 2 | 2020 | 808 | 0.060 |
Why?
|
| Glucuronosyltransferase | 1 | 2024 | 6 | 0.060 |
Why?
|
| Drug Substitution | 1 | 2024 | 29 | 0.060 |
Why?
|
| Uganda | 1 | 2024 | 194 | 0.050 |
Why?
|
| Interleukins | 1 | 2023 | 3 | 0.050 |
Why?
|
| Rilpivirine | 1 | 2023 | 7 | 0.050 |
Why?
|
| Adolescent | 2 | 2020 | 2858 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 190 | 0.050 |
Why?
|
| Overweight | 1 | 2023 | 84 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2022 | 35 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2023 | 312 | 0.050 |
Why?
|
| Models, Educational | 1 | 2021 | 3 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 11 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 112 | 0.050 |
Why?
|
| Comorbidity | 1 | 2021 | 184 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2021 | 96 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2024 | 1131 | 0.040 |
Why?
|
| Focus Groups | 1 | 2021 | 180 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 100 | 0.040 |
Why?
|
| Public Health | 1 | 2021 | 122 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2022 | 268 | 0.040 |
Why?
|
| Developing Countries | 1 | 2023 | 385 | 0.040 |
Why?
|
| Body Weight | 1 | 2020 | 110 | 0.040 |
Why?
|
| Uracil | 1 | 2019 | 7 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 21 | 0.040 |
Why?
|
| Body Composition | 1 | 2020 | 150 | 0.040 |
Why?
|
| Risk Factors | 1 | 2023 | 1431 | 0.040 |
Why?
|
| Bone Density | 1 | 2019 | 103 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 1377 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 939 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2019 | 303 | 0.040 |
Why?
|
| Prevalence | 1 | 2021 | 1149 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 654 | 0.030 |
Why?
|